Enhancement of adriamycin-induced mortality during riboflavin administration and riboflavin deficiency in rats.
Adriamycin-treated rats were monitored for survivorship while consuming a normal diet adequate in riboflavin, a normal diet and receiving daily high-dose injections of riboflavin-5'-phosphate (flavin mononucleotide, FMN), or a riboflavin-deficient diet. Each animal was compared to a corresponding pair-fed, saline-treated control. In Adriamycin-treated rats fed the normal chow diet alone, survivorship declined within 7 days and remained constant after 12 days to about 50%. Adriamycin-treated rats consuming the normal diet and injected with FMN initially showed similar survivorship; however, after 20 days survival fell to 14%. Adriamycin-treated, riboflavin-deficient rats showed within 5 days a precipitous decline in survivorship which leveled to 5%. These results suggest that during Adriamycin treatment, proper riboflavin nutriture may be a crucial determinant of survival.
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York.
G B
GB
Raiczyk
R S
RS
Rivlin
J
J
Pinto
D000818:Animals; D004317:Doxorubicin / Q000633:toxicity*; D004347:Drug Interactions; D005486:Flavin Mononucleotide / Q000378:metabolism; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D012256:Riboflavin / Q000494:pharmacology*; D012257:Riboflavin Deficiency / Q000378:metabolism / Q000401:mortality*
D005486:Flavin Mononucleotide; D004317:Doxorubicin; D012256:Riboflavin